Tags

Type your tag names separated by a space and hit enter

Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta.
PLoS One. 2021; 16(4):e0250147.Plos

Abstract

BACKGROUND

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a virus that causes COVID-19, which has become a worldwide pandemic. However, until now, there is no vaccine or specific drug to prevent or treat COVID-19.

OBJECTIVES

To find out the effective treatment as an antiviral agent for COVID-19, to determine the correlation between sociodemography with clinical outcomes and duration of treatment, and to determine the relationship between comorbidities with clinical outcomes and duration of treatment for COVID-19 patients.

METHODS

A prospective cohort study was conducted in this study. This study included only confirmed COVID-19 patients who were admitted to the hospital during April-May 2020. Convenience sampling was used to select 103 patients, but only 72 patients were suitable for inclusion.

RESULTS

The survival analysis for COVID-19 patients using the Kaplan Meier method showed that patients receiving Oseltamivir + Hydroxychloroquine had an average survival rate of about 83% after undergoing treatment of about ten days. Gender (p = 0.450) and age (p = 0.226) did not have a significant correlation with the duration of treatment for COVID-19 patients. Gender (p = 0.174) and age (p = 0.065) also did not have a significant correlation with clinical outcome of COVID-19 patients. Comorbidities showed a significant correlation with duration of treatment (p = 0.002) and clinical outcome (p = 0.014) of COVID-19 patients.

CONCLUSION

The most effective antiviral agent in this study based on treatment duration was the combination of Oseltamivir + Hydroxychloroquine. The higher the patient's average treatment duration is, the lower the average survival rate for COVID-19 patients.

Authors+Show Affiliations

Faculty of Pharmacy, Universitas 17 Agustus 1945, Jakarta, Indonesia.Faculty of Pharmacy, Universitas 17 Agustus 1945, Jakarta, Indonesia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33861777

Citation

Ramatillah, Diana Laila, and Suri Isnaini. "Treatment Profiles and Clinical Outcomes of COVID-19 Patients at Private Hospital in Jakarta." PloS One, vol. 16, no. 4, 2021, pp. e0250147.
Ramatillah DL, Isnaini S. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. PLoS One. 2021;16(4):e0250147.
Ramatillah, D. L., & Isnaini, S. (2021). Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. PloS One, 16(4), e0250147. https://doi.org/10.1371/journal.pone.0250147
Ramatillah DL, Isnaini S. Treatment Profiles and Clinical Outcomes of COVID-19 Patients at Private Hospital in Jakarta. PLoS One. 2021;16(4):e0250147. PubMed PMID: 33861777.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. AU - Ramatillah,Diana Laila, AU - Isnaini,Suri, Y1 - 2021/04/16/ PY - 2020/10/10/received PY - 2021/04/01/accepted PY - 2021/4/16/entrez PY - 2021/4/17/pubmed PY - 2021/5/15/medline SP - e0250147 EP - e0250147 JF - PloS one JO - PLoS One VL - 16 IS - 4 N2 - BACKGROUND: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a virus that causes COVID-19, which has become a worldwide pandemic. However, until now, there is no vaccine or specific drug to prevent or treat COVID-19. OBJECTIVES: To find out the effective treatment as an antiviral agent for COVID-19, to determine the correlation between sociodemography with clinical outcomes and duration of treatment, and to determine the relationship between comorbidities with clinical outcomes and duration of treatment for COVID-19 patients. METHODS: A prospective cohort study was conducted in this study. This study included only confirmed COVID-19 patients who were admitted to the hospital during April-May 2020. Convenience sampling was used to select 103 patients, but only 72 patients were suitable for inclusion. RESULTS: The survival analysis for COVID-19 patients using the Kaplan Meier method showed that patients receiving Oseltamivir + Hydroxychloroquine had an average survival rate of about 83% after undergoing treatment of about ten days. Gender (p = 0.450) and age (p = 0.226) did not have a significant correlation with the duration of treatment for COVID-19 patients. Gender (p = 0.174) and age (p = 0.065) also did not have a significant correlation with clinical outcome of COVID-19 patients. Comorbidities showed a significant correlation with duration of treatment (p = 0.002) and clinical outcome (p = 0.014) of COVID-19 patients. CONCLUSION: The most effective antiviral agent in this study based on treatment duration was the combination of Oseltamivir + Hydroxychloroquine. The higher the patient's average treatment duration is, the lower the average survival rate for COVID-19 patients. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/33861777/Treatment_profiles_and_clinical_outcomes_of_COVID-19_patients_at_private_hospital_in_Jakarta. L2 - https://dx.plos.org/10.1371/journal.pone.0250147 DB - PRIME DP - Unbound Medicine ER -